This podcast episode highlights the need to use innovative clinical trial designs in the era of increasingly personalized medicine in hematology. Listen to Dr Jurjen Versluis from Erasmus Medical Center in Rotterdam, the Netherlands, discuss his research on this topic.

As the amount of novel targeted drugs is increasing, and treatments lead to increasingly better survival outcomes, we need to think about new, adaptive designs that will result in impactful trials in shorter time. Follow Dr Versluis as he explains the different designs and methods that can be used to estimate whether trial will be efficacious or futile before its completion.

The combination of clinical trials with data from existing real-world registries, such as HARMONY or Dutch Cancer Society datasets, may also be an alternative to standard designs. By using examples of trials run by HOVON, the Dutch Hemato-oncology Foundation, Dr Versluis provides additional depth to the discussion. 

Guest: Dr Jurjen Versluis

This episode is part of a series of lectures recorded at the EHA congress in Madrid in June 2024. This podcast containing accompanying slide content is available as a video on Spotify, YouTube, and EHA Campus. More lectures will be available in the future. Stay tuned!

For more information about a past or upcoming EHA Congress, visit https://ehaweb.org/congress/

Learn More

What did you think of this podcast? Share your opinions with us in this short feedback survey.

https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe